Loading stock data…
OMER
$9.97+0.12 (+1.22%)
After Hours$9.91-0.06 (-0.60%)· Last close Jun 9
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Omeros Corporation in the Healthcare sector is trading at $9.97. Wall Street consensus targets $40.00 (1 analysts), implying a +301.2% move over the next 12 months. The stock is currently 44% below its 52-week high of $17.65, remaining 0.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +301.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 24) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$9.97
Potential Downside
0%
Whystock Fair Value$9.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Buy
Mean target$40.00+301.2%
Range$40.00 – $40.00
Fundamentals
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narso...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-136.06%
Volume
Today's trading volume
1.54M
Recent News
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now
Omeros (OMER) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Omeros (OMER) Q1 2026 Earnings Transcript
Gregory Demopulos: Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer; Dr. Cathy Melfi, our Chief Regulatory Officer; and Dr. Steve Whitaker, Vice President of Clinical. After that, David will cover the financials in more detail and then we'll open the call for questions.
Omeros Corporation Q1 2026 Earnings Call Summary
Moby summary of Omeros Corporation's Q1 2026 earnings call
Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YARTEMLEA Launch and Strategic ...
Omeros Corp (OMER) reports robust initial revenues from YARTEMLEA and secures a significant cash infusion from Novo Nordisk, despite facing financial volatility and competitive challenges.
Omeros Q1 Earnings Call Highlights
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive